# Lynn R Webster

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 118 papers | 4,555 citations | 172207 29 h-index | 106150 65 g-index |
| 120 all docs | 120 docs citations | 120 times ranked | 3855 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool. Pain Medicine, 2005, 6, 432-442. | 0.9 | 918 |
| 2 | Risk Factors for Opioid-Use Disorder and Overdose. Anesthesia and Analgesia, 2017, 125, 1741-1748. | 1.1 | 328 |
| 3 | Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain. New England Journal of Medicine, 2014, 370, 2387-2396. | 13.9 | 292 |
| 4 | Sleep-Disordered Breathing and Chronic Opioid Therapy. Pain Medicine, 2008, 9, 425-432. | 0.9 | 283 |
| 5 | An Analysis of the Root Causes for Opioid-Related Overdose Deaths in the United States. Pain Medicine, 2011, 12, S26-S35. | 0.9 | 249 |
| 6 | Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain, 2008, 137, 428-440. | 2.0 | 133 |
| 7 | Discerning suicide in drug intoxication deaths: Paucity and primacy of suicide notes and psychiatric history. PLoS ONE, 2018, 13, e0190200. | 1.1 | 112 |
| 8 | Hypoxemia in patients on chronic opiate therapy with and without sleep apnea. Sleep and Breathing, 2009, 13, 49-57. | 0.9 | 105 |
| 9 | A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. Pain, 2013, 154, 1542-1550. | 2.0 | 102 |
| 10 | Long-Term Safety of NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Peripheral Neuropathic Pain. Journal of Pain and Symptom Management, 2010, 39, 1053-1064. | 0.6 | 95 |
| 11 | Consensus Recommendations on Initiating Prescription Therapies for Opioid-Induced Constipation. Pain Medicine, 2015, 16, 2324-2337. | 0.9 | 95 |
| 12 | A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain. American Journal of Gastroenterology, 2015, 110, 725-732. | 0.2 | 87 |
| 13 | Review and Critique of Opioid Rotation Practices and Associated Risks of Toxicity. Pain Medicine, 2012, 13, 562-570. | 0.9 | 76 |
| 14 | Treatment Options for Failed Back Surgery Syndrome Patients With Refractory Chronic Pain: An Evidence Based Approach. Spine, 2017, 42, S41-S52. | 1.0 | 74 |
| 15 | Definitions and Outcome Measures of Clinical Trials Regarding Opioid-induced Constipation. Journal of Clinical Gastroenterology, 2015, 49, 9-16. | 1.1 | 71 |
| 16 | Long-term use of naldemedine in the treatment of opioid-induced constipation in patients with chronic noncancer pain: a randomized, double-blind, placebo-controlled phase 3 study. Pain, 2018, 159, 987-994. | 2.0 | 65 |
| 17 | Opioid-Induced Constipation. Pain Medicine, 2015, 16, S16-S21. | 0.9 | 59 |
| 18 | Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. Pain Medicine, 2020, 21, 714-723. | 0.9 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. Pain Medicine, 2015, 16, S22-S26. | 0.9 | 51 |
| 20 | Opioid formulations in development designed to curtail abuse: who is the target?. Expert Opinion on Investigational Drugs, 2009, 18, 255-263. | 1.9 | 50 |
| 21 | A Phase 2b, Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Pain Medicine, 2017, 18, 2350-2360. | 0.9 | 46 |
| 22 | Randomized, Double-Blind, Placebo-Controlled Study of the Abuse Potential of Different Formulations of Oral Oxycodone. Pain Medicine, 2012, 13, 790-801. | 0.9 | 43 |
| 23 | The Abuse Potential of Remoxy<sup>Â®</sup>, an Extended-Release Formulation of Oxycodone, Compared with Immediate- and Extended-Release Oxycodone. Pain Medicine, 2011, 12, 618-631. | 0.9 | 39 |
| 24 | The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature. Pain Medicine, 2015, 16, 1265-1277. | 0.9 | 37 |
| 25 | Impact of Intravenous Naltrexone on Intravenous Morphine-Induced High, Drug Liking, and Euphoric Effects in Experienced, Nondependent Male Opioid Users. Drugs in R and D, 2011, 11, 259-275. | 1.1 | 36 |
| 26 | Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. Digestive Diseases and Sciences, 2017, 62, 3568-3578. | 1.1 | 36 |
| 27 | Current status and evolving role of abuse-deterrent opioids in managing patients with chronic pain. Journal of Opioid Management, 2011, 7, 235-245. | 0.2 | 35 |
| 28 | Overdose Deaths Demand a New Paradigm for Opioid Rotation: Table 1. Pain Medicine, 2012, 13, 571-574. | 0.9 | 33 |
| 29 | Acute Pain: Effective Management Requires Comprehensive Assessment. Postgraduate Medicine, 2014, 126, 59-72. | 0.9 | 31 |
| 30 | Long-Term Safety of Remoxy<sup>Â®</sup>(Extended-Release Oxycodone) in Patients with Moderate to Severe Chronic Osteoarthritis or Low Back Pain. Pain Medicine, 2011, 12, 755-760. | 0.9 | 29 |
| 31 | Current Regulations Related to Opioid Prescribing. PM and R, 2015, 7, S236-S247. | 0.9 | 29 |
| 32 | Obtaining Adequate Data to Determine Causes of Opioid-Related Overdose Deaths. Pain Medicine, 2011, 12, S86-S92. | 0.9 | 27 |
| 33 | Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. BMC Anesthesiology, 2011, 11, 25. | 0.7 | 27 |
| 34 | Evaluation of the Tolerability of Switching Patients on Chronic FullÎ¼-Opioid Agonist Therapy to Buccal Buprenorphine. Pain Medicine, 2016, 17, pnv110. | 0.9 | 26 |
| 35 | A Review of Forensic Implications of Opioid Prescribing with Examples from Malpractice Cases Involving Opioid-Related Overdose. Pain Medicine, 2011, 12, S59-S65. | 0.9 | 25 |
| 36 | Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared with Oxycodone. Pain Medicine, 2018, 19, 307-318. | 0.9 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. Pain Medicine, 2017, 18, 1496-1504. | 0.9 | 24 |
| 38 | Daclatasvir + asunaprevir + beclabuvir Â± ribavirin for chronic <scp>HCV</scp> genotype 1â€infected treatmentâ€naive patients. Liver International, 2016, 36, 189-197. | 1.9 | 23 |
| 39 | Pharmacogenetics and Personalized Medicine in Pain Management. Clinics in Laboratory Medicine, 2016, 36, 493-506. | 0.7 | 23 |
| 40 | Benzodiazepines in Long-Term Opioid Therapy. Pain Medicine, 2013, 14, 1441-1446. | 0.9 | 22 |
| 41 | The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. Journal of Pain Research, 2015, 8, 153. | 0.8 | 22 |
| 42 | Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. Postgraduate Medicine, 2017, 129, 102-110. | 0.9 | 22 |
| 43 | Assessment of Pharmacodynamic Effects Following Oral Administration of Crushed Morphine Sulfate and Naltrexone Hydrochloride Extended-Release Capsules Compared with Crushed Morphine Sulfate Controlled-Release Tablets and Placebo in Nondependent Recreational Opioid Users. Pain Medicine, 2013, 14, 1173-1186. | 0.9 | 21 |
| 44 | Analysis of opioid-mediated analgesia in Phase III studies of methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. Journal of Pain Research, 2015, 8, 771. | 0.8 | 20 |
| 45 | A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. Pain Medicine, 2015, 17, pnv020. | 0.9 | 20 |
| 46 | Efficacy and Safety of Dual-Opioid Therapy in Acute Pain. Pain Medicine, 2012, 13, S12-S20. | 0.9 | 19 |
| 47 | Methadone-related deaths. Journal of Opioid Management, 2005, 1, 211-217. | 0.2 | 19 |
| 48 | The Economic Impact of Opioid Use in the Management of Chronic Nonmalignant Pain. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 891-899. | 0.5 | 18 |
| 49 | A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. Journal of Opioid Management, 2010, 6, 329-340. | 0.2 | 18 |
| 50 | Comparison of Subjective Effects of Extended-Release Versus Immediate-Release Oxycodone/Acetaminophen Tablets in Healthy Nondependent Recreational Users of Prescription Opioids: A Randomized Trial. Postgraduate Medicine, 2014, 126, 20-32. | 0.9 | 17 |
| 51 | A 12-week extension study to assess the safety and tolerability of naloxegol in patients with noncancer pain and opioid-induced constipation. Journal of Opioid Management, 2016, 12, 405-419. | 0.2 | 17 |
| 52 | The association of pain interference and opioid use with healthcare utilization and costs, and wage loss among adults with osteoarthritis in the United States. Journal of Medical Economics, 2019, 22, 1192-1201. | 1.0 | 16 |
| 53 | Evaluation of the abuse potential of difelikefalin, a selective kappaâ€opioid receptor agonist, in recreational polydrug users. Clinical and Translational Science, 2022, 15, 535-547. | 1.5 | 15 |
| 54 | Comparative Effects of Morning vs Evening Dosing of Extended-Release Hydromorphone on Sleep Physiology in Patients with Low Back Pain: A Pilot Study. Pain Medicine, 2015, 16, 460-471. | 0.9 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Chronic Pain and the Opioid Conundrum. Anesthesiology Clinics, 2016, 34, 341-355. | 0.6 | 14 |
| 56 | Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class. Pain Medicine, 2018, 19, 1195-1205. | 0.9 | 14 |
| 57 | Medical Management of Chronic Low Back Pain: Efficacy and Outcomes. Neuromodulation, 2014, 17, 18-23. | 0.4 | 13 |
| 58 | Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users. Journal of Clinical Pharmacology, 2020, 60, 1189-1197. | 1.0 | 13 |
| 59 | Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patientsâ€‰â‰¥â€‰65 Years of Age. Drugs and Aging, 2020, 37, 271-279. | 1.3 | 13 |
| 60 | Intravenous abuse potential study of oxycodone alone or in combination with naltrexone in nondependent recreational opioid users. American Journal of Drug and Alcohol Abuse, 2016, 42, 539-549. | 1.1 | 12 |
| 61 | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Drug Liking Study on a Novel Abuse-Deterrent Formulation of Morphineâ€”Morphine ARER. Pain Medicine, 2016, 18, pnw213. | 0.9 | 12 |
| 62 | Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) vs Extended-Release Morphine Administered Intranasally in Nondependent Recreational Opioid Users. Pain Medicine, 2016, 18, pnw219. | 0.9 | 12 |
| 63 | Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. Pain Medicine, 2016, 18, pnw174. | 0.9 | 12 |
| 64 | An Online Survey of Patientsâ€™ Experiences Since the Rescheduling of Hydrocodone: The First 100 Days. Pain Medicine, 2016, 17, 1686-1693. | 0.9 | 12 |
| 65 | Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioidâ€induced Constipation. Pain Practice, 2018, 18, 505-514. | 0.9 | 12 |
| 66 | Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach. Pain Medicine, 2020, 21, 992-1004. | 0.9 | 12 |
| 67 | A Longitudinal Study of the Association of Opioid Use with Change in Pain Interference and Functional Limitations in a Nationally Representative Cohort of Adults with Osteoarthritis in the United States. Advances in Therapy, 2020, 37, 819-832. | 1.3 | 12 |
| 68 | Eight Principles for Safer Opioid Prescribing. Pain Medicine, 2013, 14, 959-961. | 0.9 | 11 |
| 69 | Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. Journal of Pain Research, 2018, Volume 11, 1503-1510. | 0.8 | 11 |
| 70 | Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial. Journal of Addictive Diseases, 2016, 35, 325-338. | 0.8 | 10 |
| 71 | Desmetramadol Has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. Journal of Pain, 2019, 20, 1218-1235. | 0.7 | 10 |
| 72 | Eight principles for safer opioid prescribing and cautions with benzodiazepines. Postgraduate Medicine, 2015, 127, 27-32. | 0.9 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Measurement of Drug Liking in Abuse Potential Studies: A Comparison of Unipolar and Bipolar Visual Analog Scales. Journal of Clinical Pharmacology, 2017, 57, 266-274. | 1.0 | 9 |
| 74 | The Physiology and Maintenance of Respiration: A Narrative Review. Pain and Therapy, 2020, 9, 467-486. | 1.5 | 9 |
| 75 | Abuse Potential with Oral Route of Administration of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. Pain Medicine, 2017, 18, 61-77. | 0.9 | 8 |
| 76 | Ending Unnecessary Opioid-Related Deaths: A National Priority. Pain Medicine, 2011, 12, S13-S15. | 0.9 | 7 |
| 77 | Opioid Titration and Conversion in Patients Receiving Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules. Postgraduate Medicine, 2011, 123, 155-164. | 0.9 | 7 |
| 78 | Methadone Side Effects: Constipation, Respiratory Depression, Sedation, Sleep-Disordered Breathing, and the Endocrine System. , 2013, , 39-49. | | 7 |
| 79 | Opioid abuse-deterrent strategies: role of clinicians in acute pain management. Postgraduate Medicine, 2016, 128, 76-84. | 0.9 | 7 |
| 80 | Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects. Pain Research and Management, 2018, 2018, 1-10. | 0.7 | 7 |
| 81 | <p>A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy</p>. Journal of Pain Research, 2020, Volume 13, 605-612. | 0.8 | 7 |
| 82 | Unintended Harm from Opioid Prescribing Guidelines. Pain Medicine, 2009, 10, 285-286. | 0.9 | 6 |
| 83 | Oral methylnaltrexone is efficacious and well tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain receiving concomitant methadone. Journal of Pain Research, 2018, Volume 11, 2509-2516. | 0.8 | 6 |
| 84 | A PhaseÂI Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive. Advances in Therapy, 2020, 37, 4685-4696. | 1.3 | 6 |
| 85 | Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. Journal of Pain Research, 2021, Volume 14, 2179-2189. | 0.8 | 6 |
| 86 | Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation. Clinical Gastroenterology and Hepatology, 2022, 20, 855-863. | 2.4 | 6 |
| 87 | Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain. Pain Management, 2011, 1, 417-425. | 0.7 | 5 |
| 88 | American Academy of Pain Medicine Response to PROP Petition to the FDA That Seeks to Limit Pain Medications for Legitimate Noncancer Pain Sufferers. Pain Medicine, 2012, 13, 1259-1264. | 0.9 | 5 |
| 89 | Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide. Harm Reduction Journal, 2012, 9, 13. | 1.3 | 5 |
| 90 | Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users. Pain Medicine, 2018, 19, 2438-2449. | 0.9 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation. Pain Medicine, 2019, 20, 747-757. | 0.9 | 5 |
| 92 | Atypical opioids and their effect on respiratory drive. Journal of Opioid Management, 2021, 17, 109-118. | 0.2 | 5 |
| 93 | Correlation of Subjective Effects with Systemic Opioid Exposure from Fixed-Dose Combinations of Oxycodone/Acetaminophen in Recreational Users of Prescription Drugs. Pain Medicine, 2015, 17, n/a-n/a. | 0.9 | 4 |
| 94 | Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids. Postgraduate Medicine, 2015, 127, 13-21. | 0.9 | 3 |
| 95 | Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients. Postgraduate Medicine, 2019, 131, 225-229. | 0.9 | 3 |
| 96 | Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users. Current Medical Research and Opinion, 2019, 35, 503-512. | 0.9 | 3 |
| 97 | Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy Subjects. Journal of Pain Research, 2021, Volume 14, 513-526. | 0.8 | 3 |
| 98 | Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared with oxycodone alone in nondependent, recreational opioid users. Substance Abuse and Rehabilitation, 2012, 3, 101. | 1.6 | 2 |
| 99 | Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pooled analysis of three clinical trials. Current Medical Research and Opinion, 2016, 32, 563-572. | 0.9 | 2 |
| 100 | Human abuse potential studies of abuse-deterrent opioids: lessons from oral and intranasal studies with morphine abuse-deterrent, extended-release, injection-molded tablets. Current Medical Research and Opinion, 2018, 34, 893-901. | 0.9 | 2 |
| 101 | Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study. Advances in Therapy, 2019, 36, 1730-1740. | 1.3 | 2 |
| 102 | Interpreting labels of abuse-deterrent opioid analgesics. Journal of Opioid Management, 2017, 13, 415-423. | 0.2 | 2 |
| 103 | Poster 526 Abuse Quotient of Orally Administered MNK-795 Extended-Release Oxycodone/Acetaminophen Tablets vs Immediate-Release Oxycodone/Acetaminophen Tablets in Recreational Users of Prescription Opioids. PM and R, 2014, 6, S370-S371. | 0.9 | 1 |
| 104 | Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study. Therapeutic Advances in Drug Safety, 2019, 10, 204209861882127. | 1.0 | 1 |
| 105 | Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory Depression. Current Clinical Pharmacology, 2021, 16, . | 0.2 | 1 |
| 106 | Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. Journal of Opioid Management, 2017, 13, 379-389. | 0.2 | 1 |
| 107 | Risk Mitigation Strategies. , 2016, , 163-180. | | 1 |
| 108 | A nasal abuse potential randomized clinical trial of REMOXYÂ® ER, a high-viscosity extended-release oxycodone formulation. Journal of Opioid Management, 2018, 14, 437-443. | 0.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Effects of buprenorphine buccal film and oral oxycodone on pupil diameter in a respiratory study. Journal of Opioid Management, 2022, 18, 181-190. | 0.2 | 1 |
| 110 | Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial. Pain and Therapy, 2022, 11, 817-825. | 1.5 | 1 |
| 111 | It Takes Many True Leaders to Become a Top-Tier Pain Organization. Pain Medicine, 2014, 15, 3-3. | 0.9 | 0 |
| 112 | Poster 427 Pharmacodynamic Effects From a Category 3 Intranasal Human Abuse Potential Study of an Abuseâ€Deterrent, Extendedâ€Release Morphine Product Candidate in Nondependent, Recreational Opioid Users. PM and R, 2016, 8, S300-S301. | 0.9 | 0 |
| 113 | Opioid-sparing Effects of SoluMatrix Indomethacin in a Phase 3 Study in Patients With Acute Postoperative Pain. Clinical Journal of Pain, 2018, 34, 138-144. | 0.8 | 0 |
| 114 | Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. Pain Medicine, 2018, 19, 1597-1612. | 0.9 | 0 |
| 115 | The Prescription Drug Abuse Epidemic and Emerging Prescribing Guidelines. , 2018, , 389-394.e1. | | 0 |
| 116 | Doctor driven problem or doctor driven solution?. Journal of Opioid Management, 2017, 13, 351-352. | 0.2 | 0 |
| 117 | Pharmacogenetics of Pain: The Future of Personalized Medicine. , 2018, , 435-445. | | 0 |
| 118 | Drug trafficking, good faith, and legal standards to convict: How the United States Supreme Court is about to affect every prescriber in America. Journal of Opioid Management, 2022, 18, 203-204. | 0.2 | 0 |